Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing firstname.lastname@example.org or calling +44 (0)1707 367554.
Flexibility to suit your patients’ needs with administration options that include the ability to self-administer at home
The RoACTEMRA IV and SC formulations have demonstrated comparable efficacy and safety in RA,1 so you can treat with confidence regardless of which administration option you use*
RoACTEMRA® ACTPen Autoinjector
RoACTEMRA® Pre-filled Syringe
RoACTEMRA® IV Infusion
Subcutaneous RoACTEMRA® is available for home delivery to suit the needs of your patients
*The first dose should be administered under the supervision of an Health Care Professional for both new RoACTEMRA® patients and RA patients switching from RoACTEMRA® IV.
IV: Intravenous therapy, SC: subcutaneous, RA: Rheumatoid Arthritis
- Burmester GR et al. Ann Rheum Dis. 2014;73:69–74.
Date of preparation: September 2021